

health disparity populations. NIH defines health disparity populations as racial and ethnic minority populations, less privileged socioeconomic status (SES) populations, underserved rural populations, sexual and gender minorities (SGM), and any subpopulations that can be characterized by two or more of these descriptions. For more information please refer to NIH definition of Health Disparity.

Respondents are asked to address the following topics in the nomination survey:

(1) Identify the drug, vaccine, or dietary supplement for this nomination. *If applicable, please include generic name of drug or medication.*

(2) Indicate if this nomination is for a:

- a. drug,
- b. vaccine,
- c. dietary supplement.

(3) Indicate the category of condition for the research question for the nominated drug, vaccine, or dietary supplement. *If there are multiple categories per drug, vaccine, or dietary supplement, please submit a separate nomination for each one.*

a. Pregnancy- or postpartum-specific conditions (e.g., including but not limited to preterm labor, hyperemesis, labor induction, pre-eclampsia, postpartum hemorrhage).

b. Lactation-specific conditions (e.g., including but not limited to low milk supply, mastitis).

c. General medical conditions that may occur in pregnant, postpartum, and lactating persons (e.g., including but not limited to asthma, depression, diabetes, cardiac disease, STIs, HIV/AIDS, CMV, other infectious disease conditions).

(4) Indicate whether the drug, vaccine, or dietary supplement is used to treat or prevent a condition in:

- a. the mother,
- b. the fetus,
- c. both mother and fetus.

(5) Indicate the therapeutic indication that the drug, vaccine, or dietary supplement proposed in this nomination is intended to treat or prevent.

(6) If known, describe the proposed research question and rationale for urgency of need of the nominated drug, vaccine, dietary supplement, including existing evidence and feasibility of the proposed research question.

(7) If known, identify the study design and population that would be most effective in providing the needed evidence for the proposed nomination and the impact this evidence will have on clinical care.

(8) If applicable, describe research-related gaps and needs to enable or

facilitate the conduct of proposed studies, such as, but not limited to, biomarkers or other drug development tools, research infrastructure or collaborations, or workforce training needs.

(9) Describe any other factors to consider in the process of prioritizing research needs for drugs, vaccines, and dietary supplements used by pregnant, postpartum, and lactating persons.

To respond to this RFI, nominations must be made via the nomination form, which will be made available through September 29, 2023. Nominations submitted via email will not be considered. All responses will be compiled into a database that will be reviewed by a committee of stakeholder representatives, to be identified by the NICHD. The review will result in a preliminary priority list. An inaugural stakeholder meeting to review the final priority list and provide updates to the PRGLAC prioritization process will occur at a future date.

Responses to this RFI are voluntary and may be submitted anonymously. Please do not include any personally identifiable information or any information that you do not wish to make public. You may voluntarily include your name and contact information with your response. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of the Federal Government unless required by law. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. Other than your name and contact information, the Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information.

Alison N. Cernich,

Deputy Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.

[FR Doc. 2023-10960 Filed 5-22-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group Integrative Myocardial Physiology/Pathophysiology B Study Section.

Date: June 20–21, 2023.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Alexandria Old Town, 1900 Diagonal Road, Alexandria, VA 22314.

Contact Person: Kirk E Dineley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 806E, Bethesda, MD 20892, (301) 867-5309, dineleyke@csr.nih.gov.

Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group Brain Injury and Neurovascular Pathologies Study Section.

Date: June 20–21, 2023.

Time: 8:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

Contact Person: Alexander Yakovlev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5206, MSC 7846, Bethesda, MD 20892, 301-435-1254, yakovleva@csr.nih.gov.

Name of Committee: Vascular and Hematology Integrated Review Group Integrative Vascular Physiology and Pathology Study Section.

Date: June 20–21, 2023.

Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: The Bethesda Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Bukhtiar H Shah, DVM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4120,

MSC 7802, Bethesda, MD 20892, (301) 806-7314, shahb@csr.nih.gov.

Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group Drug and Biologic Therapeutic Delivery Study Section (DBTD).

Date: June 20–21, 2023.

Time: 8:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852.

Contact Person: Janice Duy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20892, 301–594–3139 janice.duy@nih.gov.

Name of Committee: Genes, Genomes, and Genetics Integrated Review Group Genetics of Health and Disease Study Section.

Date: June 20–21, 2023.

Time: 9:00 a.m. to 8:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Ave., Bethesda, MD 20814.

Contact Person: Christopher Payne, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 2208, Bethesda, MD 20892, 301–402–3702, christopher.payne@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel Translational Immuno-Oncology.

Date: June 20–21, 2023.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Maria Elena Cardenas-Corona, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Bethesda, MD 20817, 301–867–5309, maria.cardenas-corona@nih.gov.

Name of Committee: Biology of Development and Aging Integrated Review Group Drug Discovery and Molecular Pharmacology C Study Section.

Date: June 20–21, 2023.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Jeffrey Smiley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD 20892, (301) 272–4596, smileyja@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 17, 2023.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10894 Filed 5–22–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Environmental Determinants of Disease Study Section (EDD), June 08, 2023, 09:00 a.m. to June 09, 2023, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on May 03, 2023, 88 FR 27918 Doc 2023–09381.

This meeting is being amended to change the time from 9:00 a.m. to 6:00 p.m. to 8:30 a.m. to 8:00 p.m. The meeting is closed to the public.

Dated: May 17, 2023.

David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10898 Filed 5–22–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to the Deputy Director for Intramural Research.

The meeting will be held as a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: <https://videocast.nih.gov/>.

Name of Committee: Advisory Committee to the Deputy Director for Intramural Research.

Date: June 29, 2023.

Time: 12:00–4:00 p.m. EST.

Agenda: The NIH Lasker Clinical Research Scholars Program supports clinical

researchers in the early stages of their independent research careers. In this meeting the Lasker Scholar program will be evaluated by a panel of outside reviewers.

Place: National Institutes of Health, 1 Center Drive, Building 1, Room 160, Bethesda, MD 20892, (Virtual Meeting).

This meeting is a virtual meeting via Zoom and can be accessed at: [https://nih.zoomgov.com/j/1603953532?](https://nih.zoomgov.com/j/1603953532?pwd=ekhzWjFGQy9MN2ljeHRtRFRVSzBWdz09)

[pwd=ekhzWjFGQy9MN2ljeHRtRFRVSzBWdz09](https://nih.zoomgov.com/j/1603953532?pwd=ekhzWjFGQy9MN2ljeHRtRFRVSzBWdz09).

Meeting ID: 160 395 3532.

Passcode: 504446.

One tap mobile:

+16692545252,,1603953532#,,,,*504446# US (San Jose)

+16468287666,,1603953532#,,,,*504446# US (New York)

Dial by your location:

+1 669 254 5252 US (San Jose)

+1 646 828 7666 US (New York)

+1 646 964 1167 US (US Spanish Line)

+1 669 216 1590 US (San Jose)

+1 415 449 4000 US (US Spanish Line)

Find your local number: <https://nih.zoomgov.com/u/adXt6RfRSZ>.

Contact Person: Margaret McBurney, Management Analyst, Office of the Deputy Director for Intramural Research, National Institutes of Health, 1 Center Drive, Room 160, Bethesda, MD 20892–0140, (301) 496–1921, mmcburney@od.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Office of Intramural Research home page: <http://sourcebook.od.nih.gov/>.

Dated: May 17, 2023.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10896 Filed 5–22–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Library of Medicine Notice of Meeting Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Library of Medicine Special Emphasis Panel, June 16, 2023, 12:00 p.m. to 6:00 p.m. This notice was published in the **Federal Register** on March 23, 2023, 88 FR 56, Page 17587.

This notice is being amended to change the date to July 21, 2023, 11:00 a.m. to 5:00 p.m. The meeting is closed to the public.